Bisphosphonates in bone diseases other than osteoporosis. (Q34540323)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11858352 AND SRC:MED&resulttype=core&format=json

7 December 2019

review article

1 reference

title

Bisphosphonates in bone diseases other than osteoporosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11858352 AND SRC:MED&resulttype=core&format=json

7 December 2019

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11858352 AND SRC:MED&resulttype=core&format=json

7 December 2019

author name string

Philippe Orcel

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11858352 AND SRC:MED&resulttype=core&format=json

7 December 2019

publication date

1 January 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11858352 AND SRC:MED&resulttype=core&format=json

7 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11858352 AND SRC:MED&resulttype=core&format=json

7 December 2019

volume

69

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11858352 AND SRC:MED&resulttype=core&format=json

7 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11858352 AND SRC:MED&resulttype=core&format=json

7 December 2019

page(s)

19-27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11858352 AND SRC:MED&resulttype=core&format=json

Alendronate for the Treatment of Osteoporosis in Men

7 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Treatment of bone diseases with bisphosphonates, excluding osteoporosis

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Bisphosphonates in the treatment of malignant bone disease

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Effect of daily etidronate on the osteolysis of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Clodronate decreases the frequency of skeletal metastases in women with breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Reduction in new metastases in breast cancer with adjuvant clodronate treatment

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

The management of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Paget's disease: acquired resistance to one aminobisphosphonate with retained response to another

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Pamidronate in the treatment of Paget's disease.

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Long-Term Effects of Intravenous Pamidronate in Fibrous Dysplasia of Bone

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Long-Term Aminobisphosphonate Treatment of Fibrous Dysplasia: Spectacular Increase in Bone Density

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Long-Term Effects of Bisphosphonates on the Growing Skeleton: Studies of Young Patients with Severe Osteoporosis

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Treatment of severe, recalcitrant reflex sympathetic dystrophy: assessment of efficacy and safety of the second generation bisphosphonate pamidronate

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Bisphosphonate therapy of reflex sympathetic dystrophy syndrome

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fractures

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Relationship between urinary pyridinium cross-links, disease activity and disease subsets of ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Short-Term Effects of Pamidronate in Patients with Gaucher's Disease and Severe Skeletal Involvement

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Diphosphonates for periarticular ossification

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(01)00336-0

7 January 2021

10.1016/S1297-319X(01)00336-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11858352 AND SRC:MED&resulttype=core&format=json

7 December 2019

1 reference